Infographic.pdf (655.8 kB)
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study
mediaposted on 2022-02-11, 12:15 authored by Adis journals on behalf of, Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L. Arnold, Jelena Drulovic, Elzbieta Jasinska, James D. Bowen, Donald Negroski, Robert T. Naismith, Samuel F. Hunter, Mark Gudesblatt, Hailu Chen, Jennifer Lyons, Sai L. Shankar, Shivani Kapadia, Jason P. Mendoza, Barry A. Singer
The above infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2022.